QULLA supports leadership teams, investors and transaction partners with independent quality and CMC assessments that reveal whether an asset or organization can execute its development and manufacturing plans.
The assessment connects technical evidence with business consequences. It distinguishes manageable gaps from risks that could affect development timelines, regulatory credibility, supply continuity or deal value.
Support is available for in-licensing, out-licensing, biotech asset evaluation, CDMO acquisitions, private-equity diligence and strategic partnerships.
Yes. Desktop review can be combined with management interviews and on-site quality or manufacturing assessment where appropriate.
Explore all QULLA services · Read the Purple Papers · About Richard van Ewijk
We work with organizations where the stakes are high and quality excellence is non-negotiable — from advisory to hands-on execution.
Whether entering Phase I or scaling toward later-stage development, we help build quality infrastructure that matches ambition without overbuilding for the current stage.
We help CDMOs sharpen their quality positioning, strengthen governance structures, and demonstrate the operational robustness that clients and regulators demand.